Sells telehealth consultations and prescriptions, from hair loss to weight loss, by subscription.
$29.13close as of 2026-10-22
-38.6% over 1Y · 54.3 points behind the S&P 500
HIMSS&P 500 (SPY), rebased to HIMS's first close
“Can international expansion and higher subscriber spending restore profitability as Hims & Hers limits compounded weight loss medicines?”
Editorial note · updated 2026-10-02
The TenQ Radar
Hims & Hers Health in 36 checks
Hims & Hers Health on the TenQ Radar: value, growth, quality, health, shareholder returns and trend. The fuller the shape, the stronger the company. Behind each axis are six pass-or-fail checks from its filings, spelled out in the chapters below. Point at an axis to see them.
The business itself is the question here: 12 of 36 checks passed.
The Hims & Hers Health story
What drives Hims & Hers Health, what its price assumes and what could change the story, written from its own filings.
Growth has broadened. Revenue rose 38% in the quarter to June 2026 as subscriber spending increased and the Eucalyptus acquisition expanded the international business.
More revenue, less profit. Gross margin fell to 64% in the quarter to June 2026, while legal contingencies, acquisition costs, and restructuring contributed to a net loss of $86.3 million.
Expansion brings obligations. At the end of June 2026, Hims & Hers had $1.4 billion of debt against $841 million of cash and short-term investments, alongside deferred acquisition payments.
Q2 '26 · quarter to 30 June 2026 · reported 10 August 2026 · Earnings release ↗
Revenue$753M+38%vs 2025+24%vs Q1
Earnings-$86M-$129Mvs 2025+$6Mvs Q1
Against its own guidance
This quarter▲Beat its guidance by 7.6%
Actual $753M
Guided $680M to $700M
Revenue came in above the top of the range it guided in May 2026.
Full year 2026▲Raised its outlook by 10%
Was $2.8B to $3.0B
Now $3.1B to $3.3B
Measured at the midpoint, against the range it guided in May 2026. +36% on 2025.
Next quarter▲Guides 18% growth on this quarter
This quarter $753M
Guided $880M to $900M
Measured at the midpoint of its range. +49% on Q3 '25.
What the release says
Highlights
Subscribers reached nearly 2.9 million, up 19% year-over-year, and monthly revenue per average subscriber increased 21% to $92 in Q2 2026.
The company raised its full-year 2026 revenue guidance to a range of $3.1 billion to $3.3 billion and updated Adjusted EBITDA guidance to $275 million to $325 million.
What management expects
For the third quarter 2026, the company expects revenue of $880 million to $900 million and Adjusted EBITDA of $75 million to $95 million, reflecting an Adjusted EBITDA margin of 9% to 11%.
For the full year 2026, the company expects revenue of $3.1 billion to $3.3 billion and Adjusted EBITDA of $275 million to $325 million, reflecting an Adjusted EBITDA margin of 9% to 10%.
Key risks
New The company's investments in and use of artificial intelligence may not produce the expected benefits and could result in increased costs, regulatory scrutiny, customer dissatisfaction, or reputational harm if AI-enabled capabilities fail to perform as intended or generate biased or inaccurate outputs.
New Although the company monitors influencer marketing, it could be held responsible for false, misleading, or unlawful content posted by influencers, potentially resulting in fines, monetary liabilities, or required changes to marketing practices that could adversely impact business and reputation.
The company faces significant regulatory risk related to its offerings, especially compounded GLP-1 medications, as recent FDA and HHS statements and potential DOJ investigation could result in operational disruptions, increased costs, or reputational harm.
Rapid growth, expansion into new markets, and multiple acquisitions have placed strain on management and infrastructure, and failure to manage this growth could result in operational difficulties, increased costs, or declines in customer satisfaction.
The company operates in highly competitive markets and faces competition from large healthcare providers, retailers, pharmaceutical companies, and technology firms, which could impact its ability to attract and retain customers and providers.
Disruption to the global supply chain, including evolving laws and regulations, could result in delays in product availability, increased compliance costs, or the need to shift to different suppliers, affecting operations and financial results.
AI summary of the company's filings, every number checked against them · 8 October 2026 · Sources: earnings release, 10-K, 10-Q
Earnings alerts
An email when Hims & Hers Health reports, with its results and highlights. Free with a watchlist account.
I
Value
●●●●●●2/6
Expensive against its own history and its sector (judged on sales, as it is not yet profitable): the price asks a lot of the business.
-no history
2.6xown 7-year median 2.8x
0.9%cash earned per $ of price
-whole-business multiple
Valuation history
Is HIMS's P/E, P/S or P/B high or low against its own past?
Year
P/E
P/S
P/B
2024
33.3084
2.8433
8.8063
2025
88.9304
4.8626
21.1036
2026
-
2.6362
20.9719
◌ 2026 = at the latest close (2026-10-22), over the trailing twelve months; earlier years are annual averages · the last point is at the latest close (2026-10-22); earlier quarters use that quarter's average price over the trailing twelve months to it
→At 2.6x sales, the market is paying about what it has typically paid HIMS's own 7-year median of 2.8x. Neither a bargain nor a stretch by its own standard.
What this measures
What the market has paid for each dollar of earnings, sales or book value, every year, with today's multiple as the last point and the median drawn across.
What good looks like. There is no good level. What matters is the distance from the company's own history, and whether the business has changed enough to justify it.
If it rises or falls. A multiple above its own median means the market expects more than it used to, so more has to go right. Below the median means the opposite, and the question is whether the pessimism is deserved. A multiple can also fall because earnings rose, which is the good way.
Free cash flow yield
What is HIMS's free cash flow yield at today's price?
Period
FCF yield
2019
-0.2191
2020
-0.0114
2021
-0.0171
2022
-0.0315
2023
0.0268
2024
0.0472
2025
0.005
2026
0.0091
◌ 2026 = at the latest close (2026-10-22), over the trailing twelve months; earlier years are annual averages · the last point is at the latest close (2026-10-22); earlier quarters use that quarter's average price over the trailing twelve months to it
→Every dollar of market value currently buys 0.9% of annual free cash flow, less than its 7-year median of -1.1% - you are paying up for the same cash.
What this measures
Free cash flow divided by market value: the cash the business generates for every dollar you pay for it. The inverse of a price-to-cash multiple.
What good looks like. A yield at or above the company's own history, and one that compares well with what cash is worth elsewhere.
If it rises or falls. The yield rises when cash grows or the price falls, so a high yield is either a bargain or a warning about the cash continuing. Read it beside the cash conversion chart, which shows whether the cash is holding up.
Value asks what you pay for each dollar of earnings, sales or cash the business produces. A high multiple isn't automatically bad - fast growers earn theirs - but a price far above the company's own history means the market expects a lot to go right. We compare each multiple to the company's own past and to its sector, never to a universal rule.
not profitable: no free cash flow or earnings for the price to rest on
II
Growth
●●●●●●3/6
Growing, with caveats: revenue +28.0% over the last year.
+28.0%vs the year before
+64.5%compound annual
-173.4%net income growth
-compound annual
Revenue history
Is HIMS's revenue growing?
◌ amber = the company's own guidance from its earnings release: a forecast, not a reported figure · ◌ dashed quarter = Q4 derived from the annual filing minus Q1, Q2 and Q3 (the SEC never receives a Q4 report)
Period
Revenue ($)
Q1 2020
30.1M
Q2 2020
35.9M
Q3 2020
41.3M
Q4 2020
41.5M
Q1 2021
52.3M
Q2 2021
60.7M
Q3 2021
74.2M
Q4 2021
84.7M
Q1 2022
101.3M
Q2 2022
113.6M
Q3 2022
144.8M
Q4 2022
167.2M
Q1 2023
190.8M
Q2 2023
207.9M
Q3 2023
226.7M
Q4 2023
246.6M
Q1 2024
278.2M
Q2 2024
315.6M
Q3 2024
401.6M
Q4 2024
481.1M
Q1 2025
586.0M
Q2 2025
544.8M
Q3 2025
599.0M
Q4 2025
617.8M
Q1 2026
608.1M
Q2 2026
753.2M
2019
82.6M
2020
148.8M
2021
271.9M
2022
526.9M
2023
872.0M
2024
1.48B
2025
2.35B
→Revenue reached $2.3B in 2025, compounding +65% a year since 2022 though the pace has cooled. The last twelve months (+28%) ran below that pace, so growth is slowing. The trailing twelve months are already running at $2.6B, ahead of the last full year.
What this measures
The money customers paid, before any costs are taken out. Each bar is one quarter or, on the annual view, a full financial year; the last annual bar may be the trailing twelve months, which the footnote marks.
What good looks like. Growth that repeats, rather than one strong year carrying the chart, and a trailing twelve months keeping pace with the last full year.
If it rises or falls. Revenue is the hardest line to flatter, so a rise is the most trustworthy kind of growth. A fall puts pressure on every margin below it, because costs rarely come down as quickly as sales do.
Revenue by regionInsight
Where does Hims & Hers Health's revenue come from?
→Hims & Hers Health makes 83% of its revenue from United States ($622M), and that share has fallen from 99% in 2025Q1: the mix is shifting away from United States.
Source: SEC filings - segment disclosures (XBRL notes) · as at 2026-06-30
Profit history
Is HIMS's net profit growing?
◌ dashed quarter = Q4 derived from the annual filing minus Q1, Q2 and Q3 (the SEC never receives a Q4 report)
Period
Net income ($)
Q1 2020
-6.0M
Q2 2020
-981,000
Q3 2020
-5.9M
Q4 2020
-5.2M
Q1 2021
-51.4M
Q2 2021
-9.2M
Q3 2021
-15.9M
Q4 2021
-31.2M
Q1 2022
-16.3M
Q2 2022
-19.7M
Q3 2022
-18.8M
Q4 2022
-10.9M
Q1 2023
-10.1M
Q2 2023
-7.2M
Q3 2023
-7.6M
Q4 2023
1.2M
Q1 2024
11.1M
Q2 2024
13.3M
Q3 2024
75.6M
Q4 2024
26.0M
Q1 2025
49.5M
Q2 2025
42.5M
Q3 2025
15.8M
Q4 2025
20.6M
Q1 2026
-92.1M
Q2 2026
-86.3M
2019
-72.1M
2020
-18.1M
2021
-107.7M
2022
-65.7M
2023
-23.5M
2024
126.0M
2025
128.4M
→Net income was $128M in 2025, against $126M the year before. Earnings per share moved -173% over the last twelve months. Trailing twelve-month profit stands at -$142M.
What this measures
What is left after every cost, including tax and interest. The bottom line of the income statement.
What good looks like. Profit growing at least as fast as revenue, which means the business is keeping more of each sale as it gets bigger.
If it rises or falls. Profit can move for reasons revenue cannot explain - a one-off charge, a tax change, a write-down - so a single sharp year is worth checking against the margin chart before reading it as a trend.
Growth rate
How fast are HIMS's revenue and earnings growing?
Year
Revenue growth
Earnings growth
2,020
0.8018
-
2,021
0.8277
-
2,022
0.9381
-
2,023
0.6549
-
2,024
0.6932
-
2,025
0.59
0.0185
2026
0.2804
-1.7336
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · on the quarterly views, growth is the trailing twelve months against the twelve before, or a quarter against the same quarter a year earlier
→Revenue grew 28% over the twelve months to 2026-06-30, against an average of +74% a year over 2021-2025. Earnings went the other way (fell 173%) even as sales grew, so margins compressed: costs rose faster than revenue.
What this measures
How much revenue and earnings changed against the year before - the trailing twelve months against the twelve before them at each quarter, or one point per fiscal year. It is the speed of the business, not its size.
What good looks like. The earnings line above the revenue line: profits growing faster than sales means each new dollar of sales arrives more profitably than the last.
If it rises or falls. A high growth rate off a small base is easy and gets harder every year, so slowing growth in a large business is normal rather than a warning. Earnings falling while revenue grows is the combination worth understanding: costs are rising faster than sales.
Per-share growth
Are HIMS's revenue and free cash flow per share growing?
Year
Revenue per share ($)
Free cash flow per share ($)
2,019
2.3752
-2.1628
2,020
4.2077
-0.1193
2,021
1.4556
-0.1887
2,022
2.5764
-0.1649
2,023
4.1654
0.2244
2,024
6.235
0.8373
2,025
9.0912
0.2223
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→Revenue per share reached $9.09 in 2025, compounding +52% a year against +65% for HIMS as a whole. Dilution absorbed about 12.3 points of that growth. The trailing twelve months are running at $9.98 a share. Free cash flow per share stands at $0.22.
What this measures
Revenue and free cash flow, each divided by the number of shares in issue and adjusted for splits so old and new years compare honestly. Both lines rising means each share owns more of the business's sales and cash.
What good looks like. Both lines rising, and revenue per share growing at least as fast as the company's total revenue, which the answer compares. Faster means buybacks are working for you; slower means new shares are absorbing part of the growth.
If it rises or falls. This is the line that actually reaches you. A company can grow revenue every year and still shrink your slice by issuing shares faster than it grows.
Growth here is what the company has actually reported to the SEC - not a forecast. We look at the last year, the three-year pace, whether growth is speeding up or slowing down, and whether it's been consistent rather than one lucky year. Hatched bars are fourth quarters we derived from annual filings (companies file a full-year 10-K rather than a Q4 report).
Profitability is thin or negative. The growth isn't turning into money yet.
68.4%kept after direct costs
-6.0%kept after running costs
-28.9%profit on shareholders' money
-7.2%against a 10% cost of capital
-operating cash ÷ net income
Margins
What profit margin does HIMS keep on each sale?
Year
Gross
Operating
Net
2,019
0.5403
-0.9014
-0.8729
2,020
0.7358
-0.1018
-0.1218
2,021
0.7522
-0.4231
-0.396
2,022
0.7757
-0.1304
-0.1246
2,023
0.8199
-0.0338
-0.027
2,024
0.7945
0.0419
0.0854
2,025
0.7384
0.045
0.0547
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→Operating margin widened 18 points to 4% since 2022. After everything, 5 cents of each sales dollar reaches net profit.
What this measures
What survives at three points on the way down the income statement: after the direct cost of the product, after the cost of running the company, and after everything.
What good looks like. Margins that hold or widen as the business grows. The level itself varies enormously by industry, so the shape over time tells you more than the number.
If it rises or falls. A widening margin means pricing power or costs under control. A compressing one means the opposite, and it compounds: on large revenue, two points of margin is a great deal of profit.
Earnings quality
Does HIMS's operating cash flow keep up with its profit?
Year
Cash from operations
Net income
2,019
-74.9M
-72.1M
2,020
-2.5M
-18.1M
2,021
-34.4M
-107.7M
2,022
-26.5M
-65.7M
2,023
73.5M
-23.5M
2,024
251.1M
126.0M
2,025
300.0M
128.4M
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→The company generated $300M of operating cash in 2025. With no profit to compare against, cash generation is the number that matters here.
What this measures
Reported profit against the cash the business actually collected from operating. Profit is an accounting judgement; cash is not.
What good looks like. Cash at or above profit, year after year. Depreciation and other non-cash charges usually push cash above profit, so roughly 100% or more is healthy.
If it rises or falls. Cash falling behind profit for more than a year is the classic early warning: the sales are booked but the money has not arrived, and it shows up in receivables and inventory. For a lender the comparison behaves differently, because a growing loan book consumes cash.
Returns on capital
What return on equity and on capital does HIMS earn?
Year
ROE
ROA
ROCE
2,022
-0.2032
-0.1793
-0.2158
2,023
-0.0718
-0.0534
-0.0835
2,024
0.3071
0.1781
0.1273
2,025
0.2523
0.0596
0.0603
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→ROE of -29% and ROCE of -7% sit close together, so the returns come from the business itself rather than from borrowing.
What this measures
Two returns side by side: on shareholders' capital (ROE), and on all the capital in the business including debt (ROCE).
What good looks like. Both comfortably above roughly 10%, and close together. A wide gap means borrowing, not operations, is doing the work.
If it rises or falls. A high ROE built on debt looks like quality until the debt has to be refinanced. ROCE is the harder number to flatter, which is why both are shown.
Income waterfall
Where does HIMS's revenue go, from sales to net profit?
Step
Amount ($)
Revenue, last 12m
2.58B
Gross profit
1.76B
Operating income
-154.5M
Net income
-142.0M
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→Of $2.6B over the twelve months to 2026-06-30 sales, nothing reaches the bottom line - the journey from revenue to profit ends $142M underwater.
What this measures
One year of revenue, with each major cost taken out in the order the income statement takes it, ending at net profit.
What good looks like. No single step swallowing a surprising share, and a bottom line that survives all of them.
If it rises or falls. The largest step is where the business really spends its money, and it is the one to watch year to year: a step that grows faster than revenue is what margin compression looks like before it reaches the margin chart.
Cash conversion
How much of each sale does HIMS turn into free cash flow?
Period
FCF margin
2019
-0.9106
2020
-0.0283
2021
-0.1296
2022
-0.064
2023
0.0539
2024
0.1343
2025
0.0245
→2 cents of every sales dollar became free cash in 2025, up 9 points since 2022.
What this measures
Free cash flow as a share of revenue: how much of each dollar of sales survives both costs and capital spending.
What good looks like. A steady or rising share. Asset-light businesses convert far more than manufacturers, so compare a company with itself.
If it rises or falls. Falling conversion while revenue grows means growth is being bought with capital spending or working capital, which is fine while it lasts and painful when it stops.
Spending intensity
How much of its revenue does HIMS spend on capex, R&D and stock pay?
Year
Capex % of rev
Stock comp % of rev
2,019
0.0037
0.0972
2,020
0.0117
0.0392
2,021
0.0031
0.2472
2,022
0.0137
0.0813
2,023
0.0304
0.0758
2,024
0.0358
0.0625
2,025
0.1033
0.0576
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→The biggest claim on each sales dollar is capital spending, at 10% of revenue (stock compensation 6%). That share has risen since 2022, so the cost of competing is climbing.
What this measures
Capital spending, research and development, and stock compensation, each as a share of revenue. The three ways a business pays to keep its position.
What good looks like. A share that is stable or falling while revenue grows, which means the cost of competing is not rising with the business.
If it rises or falls. Rising intensity means each new dollar of sales is getting more expensive to win. Falling intensity can mean efficiency, or it can mean under-investment that shows up years later.
Marketing against revenueInsight
How much of Hims & Hers' revenue goes straight back into marketing?
dashed quarter = Q4 derived from the annual filing minus Q1, Q2 and Q3 (the SEC never receives a Q4 report)
→Hims & Hers Health spent 35% of its revenue on marketing in 2026Q2, against 52% in 2021Q1. Growth is bought before it is earned; the ratio is the price.
Source: SEC filings - XBRL financial data · as at 2026-06-30
Return on capital employed
Is HIMS's return on capital above what its capital costs?
Period
Return on capital employed
2019
-1.4464
2020
-0.1464
2021
-0.337
2022
-0.2158
2023
-0.0835
2024
0.1273
2025
0.0603
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→HIMS earns 6.0% on the capital it employs, below the 10% most investors treat as the cost of capital.
What this measures
The same return as the card above, but every filed year, against a 10% line that stands in for what capital costs.
What good looks like. Years above the line, and a trend that is flat or rising rather than drifting down towards it.
If it rises or falls. A business earning above its cost of capital creates value by growing; one earning below it destroys value by growing. The 10% line is a convention, not a law, so read the distance from it rather than the crossing.
What does “Quality” actually mean?
Quality asks whether the growth makes real money. Margins show how much of each sale survives costs; return on equity shows what shareholders earn on their capital; and the profit-to-cash comparison catches companies whose accounting profits never turn into actual cash.
TTM operating cash flow $263M on a net loss of $142M
IV
Financial health
●●●●●●1/6
The balance sheet carries real risk. Read the checks before anything else.
4.21xborrowed vs owned
0.9xnear-term bills coverage
-earnings ÷ interest bill
$841Mcash plus short-term investments
Debt & cash
How much debt does HIMS carry, and do its profits cover the interest?
Year
Total debt
Cash & investments
2,018
-
41.6M
2,019
1.5M
60.4M
2,020
0
100.2M
2,021
0
247.3M
2,022
0
179.6M
2,023
0
221.0M
2,024
0
300.3M
2,025
972.6M
577.5M
2,026
1.37B
841.0M
◌ each quarterly point is the balance sheet at that quarter end
→Debt of $1.4B sits against $841M of cash, or 4.2x shareholders' equity.
What this measures
Total borrowings against cash on hand, with debt as a multiple of shareholders' equity, and how many times profit covers the interest bill.
What good looks like. Interest covered comfortably - roughly eight times or more - and debt that is not a large multiple of equity.
If it rises or falls. Debt is only a problem when it has to be repaid or refinanced in a bad year, so cover matters more than the amount. Rising debt with rising cover is a business borrowing to grow; rising debt with falling cover is the combination that ends badly.
Near-term liquidity
Do HIMS's current assets cover the bills due within a year?
Period
Current ratio
2019
3.3754
2020
7.4261
2021
3.407
2022
4.5179
2023
2.996
2024
1.7881
2025
1.8981
◌ 2026 = the latest balance sheet (2026-06-30), not a fiscal year-end · each quarterly point is the balance sheet at that quarter end
→Near-term liquidity is tight: 0.9x of current assets against a dollar due within the year, so HIMS is relying on trading through rather than on what it already holds. That is thinner than in 2019.
What this measures
Current assets over current liabilities: what the company can turn into cash within a year against what it owes within a year.
What good looks like. Comfortably above 1.0, and not falling year after year. Below 1.0 means near-term bills exceed near-term resources, which is normal for some business models and a warning in others.
If it rises or falls. Inventory and receivables build it up; short-term borrowing and payables pull it down. A retailer that turns stock over quickly can run lower than a manufacturer and be perfectly sound.
Cash conversion
How much of HIMS's revenue arrives as operating cash?
Period
Operating cash flow / revenue
2019
-0.9068
2020
-0.0167
2021
-0.1266
2022
-0.0504
2023
0.0843
2024
0.1701
2025
0.1278
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→10.2% of every dollar HIMS sold arrived as operating cash. Up from -90.7% in 2019.
What this measures
Operating cash flow as a share of revenue: of every dollar sold, how much reached the bank before capital spending.
What good looks like. A high share, holding up or improving. It is the clearest sign that reported profit is real.
If it rises or falls. It falls when customers take longer to pay or stock builds up, and it can stay high while profit falls - which is usually the more reassuring of the two.
Shareholders' equity
Is HIMS's shareholder equity (book value) growing?
Period
Equity ($)
2018
-71.4M
2019
-139.8M
2020
-146.9M
2021
334.6M
2022
311.7M
2023
344.0M
2024
476.7M
2025
540.9M
2026
324.1M
→The company's own capital shrank from $344M in 2023 to $324M (-6%). Buybacks or losses are drawing the buffer down - the distinction matters.
What this measures
What would be left for shareholders if every asset were sold at its book value and every debt repaid. Book value, in other words.
What good looks like. Equity growing as retained profits build up, unless the company is deliberately returning more than it earns.
If it rises or falls. Equity falls for two very different reasons: buybacks, which return money to you, and losses, which do not. The distinction is the whole story, and negative equity means liabilities now exceed assets, which makes debt-to-equity and return on equity meaningless rather than alarming.
What does “Health” actually mean?
Health asks one question: can the business survive a bad year? We check whether near-term bills are covered, whether debt is modest and shrinking, whether earnings comfortably pay the interest, and - for loss-makers - how many years of cash are left at the current burn rate.
What comes back to shareholders is thin or stretched. Read the checks before counting on it.
+1.32%bought back, TTM, over market value
-at the current rate
$90Mdividends plus buybacks
$154Mlast 12m, dilutes the buybacks
+594.5%since 2019 (split-adjusted)
Capital returned vs stock comp
Do HIMS's buybacks and dividends outweigh the stock it issues to staff?
Year
Buybacks
Dividends
Stock comp
2,019
-
-
8.0M
2,020
-
-
5.8M
2,021
-
-
67.2M
2,022
-
-
42.8M
2,023
2.0M
-
66.1M
2,024
83.0M
-
92.3M
2,025
90.0M
-
135.2M
→Shareholders received $90M in buybacks in 2025. Stock compensation issued $135M of new shares in the same year, offsetting 100% of that.
What this measures
Cash returned through buybacks and dividends, alongside the value of new shares issued to employees as compensation.
What good looks like. Returns comfortably larger than stock compensation, so the share count actually falls.
If it rises or falls. A company can announce billions in buybacks while issuing nearly as much stock to staff, and the two largely cancel. What reaches you is the net effect, which is why both bars are here rather than only the buyback.
Shareholder yield
What is HIMS's shareholder yield from dividends and buybacks?
Year
Buyback yield
Dividend yield
2,019
0
-
2,020
0
-
2,021
0
-
2,022
0
-
2,023
0.0011
-
2,024
0.0198
-
2,025
0.0079
-
◌ 2026 = at the latest close (2026-10-22), over the trailing twelve months; earlier years are annual averages
→HIMS handed back 1.3% of its market value over the last twelve months, below the 2% this check asks for. All of it is buybacks; HIMS pays no dividend.
What this measures
Dividends and buybacks, each as a percentage of what the company was worth that year. The dollar chart says how much came back; this says how much came back for the price.
What good looks like. A total that clears a couple of percent and holds. Which half it comes from matters less than whether it is sustained.
If it rises or falls. A yield rises when the price falls as readily as when the payout grows, so read a jump beside the price chart before treating it as generosity.
Share count change (split-adjusted)
Is HIMS's share count rising or falling?
Year
Share-count change
2,020
0.0171
2,021
4.2832
2,022
0.0949
2,023
0.0236
2,024
0.1312
2,025
0.0905
→The share count grew 9.0% in 2025, averaging 8.2% a year over three years. Your slice of the company shrinks by that much each year unless earnings grow faster.
What this measures
The yearly change in the number of shares in issue, adjusted for splits so the years compare. A bar below zero is a falling share count, usually from buybacks; above zero, new shares were issued.
What good looks like. A flat or falling share count. Falling means each share you hold owns a little more of the business every year.
If it rises or falls. A rising count divides the same business among more owners, so your slice shrinks unless profits grow faster. This is the most direct chart on the page: it is your ownership, measured.
Dilution against what it bought
Has HIMS's revenue per share grown faster than its share count?
Change since 2019. The gap between the lines is what each share gained or lost. Share counts are split-adjusted weighted averages.
Year
Share count, change since 2019
Revenue per share, change since 2019
2,019
0
0
2,020
0.0171
0.7715
2,021
4.3736
-0.3872
2,022
4.8839
0.0847
2,023
5.0228
0.7537
2,024
5.8129
1.6251
2,025
6.4292
2.8276
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · on the quarterly view, revenue per share is the trailing twelve months over that quarter's diluted count
→HIMS's share count rose 643% from 2019 to 2025 while revenue per share grew 283%. Holders are further ahead than before, though the gain per share is smaller than the growth in the business.
What this measures
The share count and revenue per share over the same years, both indexed to 100 at the start, so the two lines can be compared directly.
What good looks like. The per-share line above the share-count line: whatever the company did with its shares, more business ended up behind each one.
If it rises or falls. Issuing shares is not automatically bad. It is bad when the money raised buys less growth than the dilution cost, which is exactly what the gap between these two lines shows.
Why compare buybacks with stock compensation?
A company can trumpet billions in buybacks while quietly issuing nearly as much stock to employees. What matters to you is the net effect: is the share count actually falling? If not, the 'return' is mostly recycling.
→HIMS is in a downtrend: the price is below the cloud where recent trading settled and that cloud is still falling. The last two weeks have rolled over, though the price is still above its level a month ago, so the fall is recent.
How the trend above is worked out
The trend read is the daily Ichimoku picture, the same indicator drawn on the chart above. Five names, and what each one is: the TENKAN is the midpoint of the last 9 sessions' high and low, the fast line; the KIJUN is the same over 26 sessions, the slow one; the two SENKOU spans are midpoints drawn 26 sessions into the FUTURE, and the band between them is the KUMO cloud - because it is drawn forward, the support for the coming weeks is already fixed and a change of its direction can be seen coming; the CHIKOU is today's close compared with the close 26 sessions back. A trend confirms itself in that order and the checks follow it: price clears the cloud, holds above both lines, the Tenkan crosses above the Kijun, the cloud ahead turns up, and the Chikou stands higher than the price a month ago. Six of six therefore means all of that at once; a price sitting inside the cloud, or below its own lines, cannot get there. The last check is the one Ichimoku cannot answer - whether the S&P 500 did better over 12 months (252 sessions), measured on the SPY ETF with dividends included, on the same adjusted basis as the stock's own price. Our figures are the last close we hold, refreshed every trading night; the chart is live. None of this says anything about the business, and it is not advice.
Are HIMS's insiders buying or selling shares with their own money?
Month
Buys ($)
Sells ($)
2023-11
0
272,453
2023-12
0
1.3M
2024-01
0
1.9M
2024-02
0
15.2M
2024-03
0
8.9M
2024-04
0
5.6M
2024-05
2.0M
16.2M
2024-06
0
25.1M
2024-07
0
8.9M
2024-08
0
6.6M
2024-09
0
7.2M
2024-10
0
15.5M
2024-11
132,260
18.1M
2024-12
0
12.8M
2025-01
0
19.5M
2025-02
0
16.3M
2025-03
0
13.9M
2025-04
0
8.2M
2025-05
0
14.1M
2025-06
0
17.9M
2025-07
0
12.8M
2025-08
0
45.8M
2025-09
0
29.4M
2025-10
0
12.7M
2025-11
0
1.1M
2025-12
0
2.4M
2026-01
0
581,566
2026-02
0
209,850
2026-03
0
2.9M
2026-04
0
2.4M
2026-05
1.2M
187,916
2026-06
0
5.2M
2026-07
0
490,519
2026-08
0
1.6M
2026-09
0
2.2M
2026-10
0
159,977
→Since November 2023, insiders bought $3M and sold $353M on the open market, a net sale of $350M. A further 478 transactions were grants, option exercises or tax withholding, which say nothing either way.
What this measures
Open-market buys and sells by the company's own officers and directors, from their Form 4 filings. Grants, option exercises and shares withheld for tax are excluded, because they are compensation rather than decisions.
What good looks like. Buying with their own money, which is the one insider action that is hard to explain away.
If it rises or falls. Selling is weak evidence: insiders sell to diversify, to buy houses, and on pre-scheduled plans set months ahead. Buying is stronger evidence, because there is only one reason to do it. The absence of any buying over a long stretch is itself worth noticing.
The record
Who did what, exactly?
Date
Insider
Role
Type
Shares
Price
Value
2026-10-14
Soleil Boughton
Chief Legal Officer
SELL
3,461
$29.06
$100,577
2026-10-01
Oluyemi Okupe
Chief Financial Officer
SELL
2,000
$29.70
$59,400
2026-09-30
Soleil Boughton
Chief Legal Officer
SELL
3,461
$29.17
$100,957
2026-09-22
Oluyemi Okupe
Chief Financial Officer
exercise
14,000
$5.01
$70,140
2026-09-22
Oluyemi Okupe
Chief Financial Officer
SELL
29,277
$29.95
$876,846
2026-09-17
Oluyemi Okupe
Chief Financial Officer
SELL
12,313
$28.82
$354,861
2026-09-16
Soleil Boughton
Chief Legal Officer
SELL
6,236
$27.86
$173,735
2026-09-15
Michael Chi
Chief Operating Officer
SELL
14,027
$28.39
$398,227
2026-09-15
Mohamed Elshenawy
CTO
SELL
7,954
$28.39
$225,814
2026-09-02
Soleil Boughton
Chief Legal Officer
SELL
3,458
$28.33
$97,965
2026-08-19
Oluyemi Okupe
Chief Financial Officer
exercise
4,938
$5.01
$24,739
2026-08-19
Oluyemi Okupe
Chief Financial Officer
SELL
4,938
$29.99
$148,111
2026-08-19
Soleil Boughton
Chief Legal Officer
SELL
25,111
$27.55
$691,808
2026-08-18
Deborah M. Autor
Chief Policy Officer
SELL
16,773
$27.85
$467,128
2026-08-17
Oluyemi Okupe
Chief Financial Officer
exercise
9,388
$5.01
$47,034
2026-08-17
Oluyemi Okupe
Chief Financial Officer
SELL
9,388
$27.89
$261,802
2026-08-14
Soleil Boughton
Chief Legal Officer
tax
21,500
$28.15
$605,225
2026-08-14
Patrick Harrison Carroll
Chief Medical Officer
tax
10,201
$28.15
$287,158
2026-08-14
Andrew Dudum
Chief Executive Officer
tax
78,859
$28.15
$2.22M
2026-08-14
Michael Chi
Chief Operating Officer
tax
47,702
$28.15
$1.34M
2026-08-14
Oluyemi Okupe
Chief Financial Officer
tax
36,437
$28.15
$1.03M
2026-08-14
Deborah M. Autor
Chief Policy Officer
tax
16,147
$28.15
$454,538
2026-08-14
Mohamed Elshenawy
CTO
tax
95,798
$28.15
$2.7M
2026-08-14
Irene Becklund
PAO
tax
6,490
$28.15
$182,694
2026-07-17
Oluyemi Okupe
Chief Financial Officer
exercise
7,163
$5.01
$35,887
2026-07-17
Oluyemi Okupe
Chief Financial Officer
SELL
7,163
$31.99
$229,168
2026-07-06
Oluyemi Okupe
Chief Financial Officer
exercise
7,163
$5.01
$35,887
2026-07-06
Oluyemi Okupe
Chief Financial Officer
SELL
7,163
$36.49
$261,351
2026-06-22
Oluyemi Okupe
Chief Financial Officer
exercise
6,376
$5.01
$31,944
2026-06-22
Oluyemi Okupe
Chief Financial Officer
SELL
18,197
$34.03
$619,217
2026-06-18
Oluyemi Okupe
Chief Financial Officer
SELL
55,383
$35.09
$1.94M
2026-06-18
Patrick Harrison Carroll
Chief Medical Officer
SELL
23,726
$35.00
$830,410
2026-06-17
Michael Chi
Chief Operating Officer
SELL
14,027
$31.50
$441,851
2026-06-17
Irene Becklund
PAO
SELL
4,490
$31.50
$141,435
2026-06-17
Mohamed Elshenawy
CTO
SELL
30,040
$31.50
$946,260
2026-06-16
Irene Becklund
PAO
SELL
7,573
$30.25
$229,083
2026-06-15
Patrick Harrison Carroll
Chief Medical Officer
tax
8,310
$30.17
$250,713
2026-06-15
Oluyemi Okupe
Chief Financial Officer
tax
39,541
$30.17
$1.19M
2026-06-15
Deborah M. Autor
Chief Policy Officer
tax
15,396
$30.17
$464,497
2026-06-15
Michael Chi
Chief Operating Officer
tax
47,699
$30.17
$1.44M
2026-06-15
Irene Becklund
PAO
tax
5,870
$30.17
$177,098
Why do the transaction types matter so much?
Most insider filings are not trades: stock grants, option exercises and tax withholding are how executives get paid, and gifts are estate planning. The signal lives in open-market transactions - a buy means an insider chose to spend their own cash on the stock. Sells are murkier: many are pre-scheduled 10b5-1 plans set months in advance. That's why the chart counts only open-market activity, and the table labels every row.
VIII
Ownership
informational
67.1%on Form 13F, 30 June 2026
4.9%officers, directors, founders
44.4%together
Top holders
Who owns Hims & Hers Health stock?
Fund managers filing Form 13F held 67.1% of the company's shares on 30 June 2026. The largest holder is BlackRock, Inc., with 12.3%. Insiders hold 4.9%.
#
Holder
Stake
Shares
Value
Change
1
BlackRock, Inc.Fund manager
12.30%
28.7M
$836M
+9.0%
2
G1 Execution Services, LLCHolds over 5% · Form 13G, 31 March 2026
6.22%
14.5M
$422M
-
3
Vanguard Portfolio Management LLCFund manager
4.53%
10.6M
$308M
+3.7%
4
Vanguard Capital Management LLCFund manager
4.09%
9.5M
$278M
+2.2%
5
Andrew DudumChief Executive Officer · Form 4, 25 August 2026
3.53%
8.2M
$240M
-
6
State Street CorpFund manager
3.49%
8.1M
$237M
+9.2%
7
Morgan StanleyFund manager
3.07%
7.2M
$208M
-19.5%
8
Divisadero Street Capital Management, LPFund manager
2.58%
6.0M
$175M
+1179.1%
9
Geode Capital Management, LLCFund manager
2.44%
5.7M
$166M
+9.3%
10
Goldman Sachs Group IncFund manager
2.22%
5.2M
$151M
+110.8%
11
JPMorgan Chase & CoFund manager
2.04%
4.8M
$139M
-9.0%
12
FMR LLCFund manager
1.85%
4.3M
$126M
+4535.2%
13
Marshall Wace, LLPFund manager
1.81%
4.2M
$123M
+482.4%
14
UBS Group AGFund manager
1.14%
2.7M
$78M
-35.9%
15
Northern Trust CorpFund manager
1.11%
2.6M
$76M
+6.5%
16
Charles Schwab Investment Management IncFund manager
1.05%
2.5M
$71M
+4.0%
17
State of Michigan Retirement SystemFund manager
1.01%
2.3M
$68M
+0.3%
18
Bank of America CorpFund manager
0.99%
2.3M
$67M
-46.9%
19
Principal Financial Group IncFund manager
0.71%
1.7M
$49M
+30.0%
20
Vanguard Fiduciary Trust CoFund manager
0.65%
1.5M
$44M
+5.0%
The full list of top holders is free with an account
Source: SEC Form 13F filings for the quarter to 30 June 2026, Schedules 13D and 13G, and Form 4. Shares on today's basis, value at the latest price.
Where does this list come from?
Fund managers with more than $100 million in US stocks report their holdings every quarter on Form 13F, up to 45 days after the quarter ends, so the fund figures are as of the last quarter end. A fund family reports as one manager, and funds together can report more than 100%: shares lent to short sellers are bought again by other funds, and both report them. Anyone holding more than 5% of a class files a Schedule 13D or 13G, and officers and directors report what they hold on Form 4 after every trade, so those rows carry their own dates. Short positions are not reported anywhere. A stake is the holder's shares as a share of all the company's shares, with other share classes converted at their market value.